Key facts
- It has raised $31.0M across 1 recorded rounds; the latest was Early Stage VC ($21.3M) in Dec 2021.
- Notable investors include New Enterprise Associates, Biovision Ventures, Lundbeckfonden BioCapital, Magnify, Pappas Capital.
- Sorriso Pharmaceuticals has filed 1 Form D with the SEC, most recently Jan 2022 ($21.3M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Sorriso Pharmaceuticals
Funding rounds
1 roundsAbout Sorriso Pharmaceuticals
Developer of disease-modifying antibodies designed for the treatment of inflammatory diseases, including Crohn's disease and ulcerative colitis. The company develops potent antibodies that can be delivered orally, providing clinical impacts similar to those of injectable antibody therapeutics, enabling healthcare providers to relieve the treatment burden for patients who rely on drugs that can only be administered via injections.
- Sector
- Healthcare
- HQ
- Sandy, UT, United States
- Founded
- 2020
- Employees
- 8
- Website
- sorrisopharma.com/
- Ownership
- Privately Held (backing)
Sorriso Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sorriso Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sorriso Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.